摘要
目的:评价单药多西他赛联合重组人血管内皮抑素治疗老年晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法:60例老年晚期NSCLC患者分为重组人血管内皮抑素联合化疗组30例,采用重组人血管内皮抑素15mg,静脉滴入,d1～d14,联合多西他赛35mg/m2,静脉滴入,d1、d8;单纯化疗组30例,采用多西他赛35mg/m2,静脉滴入,d1、d8,21d为1个周期,完成2～4个周期,评价两组的疗效和毒副反应。结果:重组人血管内皮抑素联合化疗组有效率46.7%,疾病控制率73.3%,中位疾病进展时间4.5个月;单纯化疗组有效率23.3%,疾病控制率56.6%,中位疾病进展时间3.2个月,两组比较差异有统计学意义,P<0.05。生活质量改善情况两组比较差异无统计学意义,P>0.05。主要毒副反应包括骨髓抑制白细胞减少,肝肾功能损害,恶心呕吐。结论:重组人血管内皮抑素联合多西他赛每周方案治疗老年晚期NSCLC,与单纯化疗相比能改善客观有效率,显著延长患者疾病进展时间,且毒副反应小,患者耐受性好,是安全、有效的老年晚期NSCLC治疗方案,值得临床深入研究。
OBJECTIVE：To evaluate the efficacy and safety of docetaxel combined with rh-endostatin （Endostar） in the treatment of elderly advanced non-small cell lung cancer （NSCLC）.METHODS：Sixty old patients with advanced NSCLC were divided into a treatment group and control group.In the treatment group,the patients received Endostar （15 mg,iv,d1-d14） combined with docetaxel （35 mg/m2,iv,d1,d8） as first line treatment,and in the control group,the patients received docetaxel （35 mg/m2,iv,d1,d8） as first line treatment.For 2 or 4 cycles,the efficacy and toxicity of the two groups were evaluated.RESULTS：In the treatment group,the response rate was 46.7%,the disease control rate was 73.3%,and the median time to progress was 4.5 months;in the control group,the response rate was 23.3%,the disease control rate was 56.6%,and the median time to progress was 3.2 months.There was a significant difference between the two groups （P0.05）,but there was no significant difference in quality of life between the two groups （P0.05）.The major adverse effects were neutropenia,liver and renal function damage,nausea and vomiting.CONCLUSIONS：Endostar combined with docetaxel in the treatment of elderly advanced NSCLC can improve the objective response rate and prolong the time to disease progress compared with the simple chemotherapy and without toxicity increasing.This therapy is well tolerated,safe and effective for elderly advanced NSCLC,so it is worthy of further clinical study.
出处
《中华肿瘤防治杂志》
CAS
2010年第18期1460-1462,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
浙江省卫生厅基金资助项目(2008A142)
关键词
多西他赛
癌
非小细胞肺/药物疗法
药物疗法
联合
docetaxel
carcinoma
non-small cell lung/drug therapy
drug therapy
combination
